ワークショップ10 周術期治療の到達点と課題

[WS10-1] Neoadjuvant nivolumab（N）+chemo（C）vs C in resectable NSCLC：CheckMate 816, including Japanese data

^○Tetsuya Mitsudomi¹, Jonathan Spicer², Nicholas Girard³, Mariano Provencio⁴, Changli Wang⁵, Mark M. Awad⁶, Everett E. Vokes⁷, Janis M. Taube⁸, Lorena Lupinacci⁹, Gene B. Saylors¹⁰, Fumihiro Tanaka¹¹, Moishe Liberman¹², Sung Yong Lee¹³, Aurelia Alexandru¹⁴, Manolo D Arcangelo¹⁵, Phuong Tran¹⁶, Vishwanath Gharpure¹⁶, Apurva Bhingare¹⁶, Patrick M. Forde⁸ (1.Kindai University Faculty of Medicine, Ohno-Higashi, Osaka-Sayama, Japan, 2.McGill University Health Centre, Montreal, Quebec, Canada, 3.Institut du Thorax Curie-Montsouris, Institut Curie, Paris, France, 4.Hospital Universitario Puerta de Hierro, Madrid, Spain, 5.Tianjin Lung Cancer Center, Tianjin Medical University Cancer Institute ＆ Hospital, Tianjin, China, 6.Dana-Farber Cancer Institute, Boston, MA, USA, 7.University of Chicago Medicine, Chicago, IL, USA, 8.The Bloomberg–Kimmel Institute for Cancer Immunotherapy, Johns Hopkins Medicine, The Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA, 9.Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, 10.Charleston Oncology, Charleston, SC, USA, 11.University of Occupational and Environmental Health, Kitakyushu, Japan, 12.Centre Hospitalier de l'Universite de Montreal, Montreal, Quebec, Canada, 13.Korea University Guro Hospital, Korea University College of Medicine, Seoul, Republic of Korea, 14.Institutul Oncologic Bucuresti Prof. Dr. Alexandru Trestioreanu, Bucharest, Romania, 15.Azienda Unita Sanitaria Locale della Romagna, Ravenna, Italy, 16.Bristol Myers Squibb, Princeton, NJ, USA)